AUSTIN, Texas, Aug. 10, 2016 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. today announced it conducted a new audio interview with PositiveID Corporation (“PositiveID” or the “Company”) (OTCQB:PSID), a life sciences company focused on detection and diagnostics. In the interview, which can be heard at http://smallcapvoice.com/blog/8-8-16-smallcapvoice-interview-with-positiveid-corporation-psid, Lyle L. Probst, President of PositiveID, discusses the Company’s successful detection of Zika virus on its Firefly Dx polymerase chain reaction (“PCR”) breadboard prototype pathogen detection system (“prototype system”).
PositiveID used assay partner GenArraytion, Inc.’s Aedes Aegypti MultiFLEX™ PCR test, which targets four genetic regions of the Zika virus, on PositiveID’s Firefly Dx prototype system. PositiveID is developing the Firefly Dx prototype system to be a handheld, fully automated, lab quality, real-time device able to detect bio-threats at the point of need. Currently, PCR tests are run on large lab equipment and take a minimum of four hours to deliver results. A design advantage of Firefly Dx is that it does not require additional equipment or separate steps for sample preparation and purification, unlike current lab-based equipment, thus reducing time to results as well as cost per test.
The Firefly Dx prototype system has also successfully detected a number of other pathogenic organisms including E.coli, Ebola, influenza, MRSA, MSSA, C. diff and others.
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://www.smallcapvoice.com/services.html.
About PositiveID Corporation
PositiveID Corporation is a life sciences company focused on detection and diagnostics, with an extensive patent portfolio. PositiveID specializes in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.
Statements about PositiveID's future expectations in this press release and those made in its interview with SmallCapVoice.com, including the likelihood that Firefly Dx reduces time to results as well as cost per test; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID’s actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the bio-threat detection and rapid medical testing sectors; the Company’s ability to complete development of Firefly Dx; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 12, 2016, and 10-Qs filed on May 16, 2016, November 12, 2015, and August 13, 2015, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.